However, traditional CAR T cell therapy has had limited success in solid tumors. Shipra Das, an immunooncologist at Cellectis, discussed a novel approach using transcription activation-like effector ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果